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Treatment of tuberculosis (TB) and HIV co-infections is often complicated by drug-
to-drug interactions between anti-mycobacterial and anti-retroviral agents. Rifabutin
(RFB) is an alternative to rifampin (RIF) for TB regimens and is recommended for HIV
patients concurrently receiving protease inhibitors because of reduced induction of
CYP3A4. This study sought to determine the proportion of RFB susceptible isolates
among RIF-resistant strains in a high HIV prevalence setting in South Africa. In
addition, the study explored the association between rpoB mutations and minimum
inhibitory concentrations (MIC) of RIF and RFB. A total of 189 multidrug resistant (MDR)
Mycobacterium tuberculosis isolates from the Centre for Tuberculosis repository were
analyzed. The MICs were determined using a MYCOTB Sensititre plate method and the
rpoB gene was sequenced. Of the 189 MDR isolates, 138 (73%) showed resistance
to both RIF and RFB, while 51 (27%) isolates were resistant to RIF but retained
susceptibility to RFB. The S531L was the most frequent rpoB point mutation in 105/189
(56%) isolates, followed by H526Y in 27/189 (14%) isolates. Resistance to both RIF
and RFB was found predominantly in association with mutations S531L (91/105, 87%),
H526Y (20/27, 74%), and H526D (15/19, 79%), while D516V (15/17, 88%), and L533P
(3/4, 75%) were found in RIF-resistant, RFB-susceptible isolates. This study has shown
that up to 27% of MDR-TB patients in South Africa may benefit from a treatment regimen
that includes RFB.
Keywords:Mycobacterium tuberculosis, rpoB, rifampicin, rifabutin, minimum inhibitory concentration, HIV/AIDS,
South Africa, point mutation
Frontiers in Microbiology | www.frontiersin.org 1 December 2016 | Volume 7 | Article 1947
fmicb-07-01947 December 1, 2016 Time: 17:16 # 2
Rukasha et al. Rifampin and Rifabutin MIC for M. tuberculosis
INTRODUCTION
Tuberculosis (TB) is responsible for 25% of HIV/AIDS related
mortality worldwide, with sub-Saharan Africa accounting for
79% of HIV-associated TB cases (WHO, 2015). In South Africa,
65% of TB patients are HIV-positive, and TB remains the leading
cause of death among HIV-infected individuals. Treatment of TB
in the context of HIV co-infection is challenging, due to the high
potential for drug-drug interactions in combined antimicrobial
and anti-retroviral (ARV) chemotherapy. There is an urgent
need to harmonize TB and HIV treatment through development
of compatible ARV regimens. Moreover, multidrug-resistant
(MDR) TB, defined by resistance to rifampin (RIF) and isoniazid
(INH), is emerging, particularly within high burden countries,
such as South Africa (WHO, 2015). MDR-TB is associated with
poor treatment outcomes and greatly elevated health costs.
Due to its sterilizing capacity, the inclusion of RIF in TB
treatment regimens is crucial for achievement of high cure rates
coupled with low relapse rates (CDC, 2013). However, RIF is a
potent inducer of CYP3A4 and other cytochrome P450 enzymes,
leading to reduced serum levels of protease inhibitors, used in
treatment of HIV/AIDS (CDC, 2013). Rifabutin (RFB) is an
alternative rifamycin, which has less impact on CYP3A4 activity
and improved pharmacokinetics compared to RIF (Regazzi et al.,
2014). Although the activity of RFB is comparable to that of
RIF for treatment of drug-susceptible TB, current guidelines
recommend limited use of RFB only in drug-susceptible adult
TB patients with HIV/AIDS or adults experiencing intolerance
to RIF. Widespread use of RFB has also been limited by its cost
and absence from most commercial susceptibility testing systems
(Horne et al., 2011). However, RFB costs have been lowered by its
addition to the WHO Essential Medicines List, while the recently
validated MYCOTB Sensititre plate method includes RFB in its
drug panel (Lee et al., 2014).
Resistance to both RIF and RFB is largely associated with
mutations in an 81-bp RIF resistance determining region (RRDR)
within the rpoB gene of Mycobacterium tuberculosis (Jamieson
et al., 2014). Although high-level cross-resistance between the
two rifamycins is reported, some studies have shown RFB
susceptibility in RIF-resistant strains of M. tuberculosis in
association with specific rpoB mutations (Cavusoglu et al., 2004;
Yoshida et al., 2010; Jamieson et al., 2014; ElMaraachli et al.,
2015). Thus, it has been argued that knowing the type of rpoB
mutation may have clinical implications for guiding rifamycin-
based therapeutic regimens (Sirgel et al., 2013; Berrada et al.,
2016).
Studies from low HIV settings have reported that 13–26%
of MDR-TB isolates show sensitivity to RFB (Chen et al.,
2012; Jo et al., 2013; Schon et al., 2013). However, there is
limited information on the frequency of RFB susceptibility
among MDR-TB isolates in an HIV endemic region. This
study aimed to determine the proportion of MDR strains
with RFB susceptibility in Gauteng Province, South Africa.
Gauteng is the economic hub of South Africa, with a
large migrant workforce, where 73% of TB patients are co-
infected with HIV. In addition, we examined correlations
between specific rpoB mutations and the minimum inhibitory
concentrations (MIC) of RIF and RFB among clinical MDR-TB
isolates.
MATERIALS AND METHODS
Clinical Isolates and Ethics
A total of 211 MDR-TB isolates available from the Centre for
Tuberculosis (CTB) repository were included. These isolates were
collected over the first 6 months of 2010 at the National Health
Laboratory Services (NHLS) Central TB diagnostics laboratory in
Braamfontein, Johannesburg from confirmed MDR-TB cases and
submitted for analysis to the CTB, as described (Said et al., 2016).
Ethics approval for this study was obtained from the Research
Ethics Committee of the Faculty of Health Sciences, University of
the Free State (Ref: 230408-011).
Minimal Inhibitory Concentration
Determination ofM. tuberculosis Isolates
Minimum inhibitory concentrations were determined using
a commercially available Sensititre MYCOTB plate (TREK
Diagnostics, Cleveland, OH, USA), following the manufacturer’s
instructions. The MIC test range for both RIF and RFB was from
0.12 to 16 mg/L. Resistance and sensitivity to RIF were defined
as MIC > 1 and MIC ≤ 1 mg/L, respectively, and to RFB as
MIC> 0.5 and MIC≤ 0.5 mg/L, respectively, based on laboratory
standards (CLSI, 2011).
DNA Extraction, PCR, and Sanger
Sequencing
All isolates were grown on Löwenstein–Jensen agar; genomic
DNA was extracted using the phenol-chloroform (CTAB)
method (van Embden et al., 1993). Six primer sets were used
for PCR amplification of the entire rpoB gene (Table 1). The
PCR amplification protocol consisted of a 5 min denaturation
step at 95◦C, followed by 35 cycles of 30 s at 95◦C, 30 s at 62◦C
and 50 s at 72◦C and a final extension step at 72◦C for 2 min.
Following Sanger sequencing of amplicons, mutations in rpoB
were identified by alignment to H37Rv reference strain (NCBI
Accession number AL123456; Cole, 2002) using ClustalW2 (Li
et al., 2015).
Statistical Analysis
Kruskal–Wallis tests were used to determine whether mutations
were associated with differences in RIF and RFB MICs. A Dunn
test incorporating the Benjamini–Hochberg false discovery rate
correction was performed to identify pairwise differences in RFB
MICs.
RESULTS
Of the 211 MDR isolates in the collection, MIC and sequencing
data were available for 189 (90%). The remaining 22 (10%)
isolates were excluded from analysis due to RIF resistance not
confirmed on MIC testing, contamination, or loss of viability.
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TABLE 1 | rpoB primers used to amplify RRDR region.
Primer set Forward primers (5′-3′) Reverse primers (5′-3′) Amplicon size (nt)
rpoB-RRDR GGGAGCGGATGACCACCCA GCGGTACGGCGTTTCGATGAAC 350
rpoB-2 ATGACGTACGCGGCTCCACTGTTCG GGTGGTCATCCGCTCCCGGACCAC 840
rpoB-3 CGCGGCGAACGGGCCCGTGGGCA CGGGATCACCTTGACGCTGTGCAG 675
rpoB-4 CTGTCGGTGTACGCGCGGGTCAA GGGACCGTCGGCGATCACCTGACC 621
rpoB-5 CCACGGCACTTGCGCCAACCAG CATCCGTCGCGGCACGCCGTGGGT 742
rpoB-6 CCGGTTGAGGACATGCCGTTC TCCCTTTCCCCTAACGGGTTTAGT 879
Among the 189 MDR isolates analyzed, S531L was the
most frequently observed rpoB RRDR mutation, found in
105/189 (56%) isolates, followed by H526Y in 27 (14%),
H526D in 19 (10%), D516V in 17 (9%), L533P in four
(2%), and D516G_L533P in three (2%) isolates (Table 2). Of
the 189 isolates, 138 (73%) showed resistance to both RIF
and RFB, while 51 (27%) were RIF-resistant but exhibited
RFB susceptibility. Resistance to both RIF and RFB was
predominantly associated with S531L (91/105, 87%), H526Y
(20/27, 74%), and H526D (15/19, 79%) mutations. Rifabutin
susceptibility was most commonly observed for isolates carrying
D516V (15/17, 88%) and L533P (3/4, 75%), although two of
three isolates with the double mutation D516G_L533P were
moderately resistant to RFB. Nine (5%) RIF-resistant isolates
had no mutations in the RRDR. However, three of the nine
had a mutation outside the RRDR. Two of these (V276L and
V276F) were RFB susceptible, while one (V252E) was RFB-
resistant; the remaining six had no mutations in rpoB outside the
RRDR.
The Kruskal–Wallis test showed significant association
between mutations and MICs for both RIF and RFB (Kruskal–
Wallis statistic for RIF: H = 67.699, p = 0.0001; for RFB:
H = 42.988, p = 0.0003). Dunn’s pairwise comparison with
Benjamini–Hochberg false discovery rate correction showed that
RFB MICs in D516V and L533P isolates were not significantly
different from wild type (q = 0.1317), nor from each other
(q = 0.4118), although the numbers were small (WT n = 9;
L533P n = 4; D516V n = 17). The RFB MICs for H526D
H526Y and S531L were not significantly different from each
other. However, there were significant differences between RFB
MICs in D516V isolates and those in H526D, H526Y, and
S531L (all q < 0.0001). Among isolates with the most common
RRDR mutations, there was a significantly lower median MIC
for RFB compared to RIF, with at least a threefold lower
median MIC for S531L, H526Y, and H526D; and 5- and 7-fold
lower medians for D516V and L533P, respectively (Figure 1).
Additionally, higher levels of resistance to RIF correlated with
higher resistance to RFB (Spearman’s correlation coefficient
r = 0.4511, p< 0.000001).
DISCUSSION
This study sought to determine the potential usefulness of
RFB for MDR-TB patients in a high HIV prevalence setting.
In our study population, 27% of MDR clinical isolates of
M. tuberculosis retained sensitivity to RFB. This is in agreement
with previous studies conducted in countries with relatively
low HIV prevalence, including Turkey, Canada, Bangladesh,
and Taiwan, where RFB susceptibility was found in 13–28%
of RIF-resistant clinical isolates (Cavusoglu et al., 2004; van
Ingen et al., 2011; Jamieson et al., 2014; Heysell et al., 2015).
Moreover, the strong association, we observed between levels of
resistance to RIF and RFB is consistent with other published
reports (Sirgel et al., 2013; Jamieson et al., 2014). In our
MDR isolate collection, the mutations S531L, H526Y, and
H526D were primarily associated with resistance to both drugs,
while D516V and L533P mutations were mainly associated
with RFB-susceptible isolates. Similar MICs for both RIF and
RFB have been reported for these mutations present among
clinical M. tuberculosis isolates from Turkey, the Netherlands,
and South Africa (Cavusoglu et al., 2004; van Ingen et al.,
2011; Sirgel et al., 2013). In our study, RFB MICs for D516V
isolates were significantly lower than those associated with
the most common RRDR mutations (S531L and D526Y) and
were consistent with RFB MICs reported elsewhere for this
mutation (Cavusoglu et al., 2004; Jamieson et al., 2014).
Moreover, no significant differences were found between RFB
MICs of isolates with D516V or L533P mutations and those
with wild type rpoB sequences. Interestingly, a double mutation
at positions D516V-L533P was found in isolates with lower
levels of RFB resistance. The treatment option may need to
be investigated since increased RIFB concentration are not
currently recommended due to possible toxicity issues (Sirgel
et al., 2013).
All of the rpoB mutations identified in our study collection
have been previously described and are reported in the TB
Drug Resistance Mutation Database (Sandgren et al., 2009).
Moreover, the mutations that, we found most frequently were
similar to those reported from other surveys of M. tuberculosis
clinical isolates. The S531L mutation is most often associated
with RIF-resistance, ranging from 62 to 35% of clinical
isolates surveyed (Cavusoglu et al., 2004; Campbell et al.,
2011; Jamieson et al., 2014). Nonetheless, some variations
in the relative proportions of specific rpoB mutations have
been noted in different populations. For example, while
we only found single representatives of S531R and S531W,
these mutations were found to comprise up to 10% of
clinical isolates in studies conducted in the United States
and Turkey (Cavusoglu et al., 2004; Campbell et al., 2011).
It is notable that all of the most common rpoB mutations
seen in clinical isolates occur spontaneously in in vitro
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TABLE 2 | Mutations in rpoB RRDR and MICs of RIF and RFB for all MDR isolates.
Mutation Sequence change Total number of isolates Number of RFB-S (% total) MIC (ug/ml) Number of
isolates
Median MIC
RIF RFB RIF RFB
S531L TCG > TTG 105 14 (13) 16 16 4 16 2
16 8 5
4 8 1
16 4 21
16 2 31
8 2 1
16 1 28
16 0.5 10
16 0.25 2
8 0.12 1
4 0.5 1
H526Y CAG > TAC 27 7 (26) 16 16 5 16 2
16 8 2
16 4 3
16 2 6
16 1 4
16 0.5 5
16 0.25 2
H526D CAC > GAC 19 4 (21) 16 16 2 16 2
16 8 4
16 4 2
16 2 5
16 1 2
16 0.5 4
D516V GAC > GTC 17 15 (88) 16 4 1 4 0.12
16 1 1
16 0.25 1
8 0.25 1
2 0.25 1
16 0.12 1
8 0.12 3
4 0.12 5
2 0.12 3
L533P CTG > CCC 4 3 (75) 16 1 1 16 0.31
16 0.5 1
16 0.12 2
D516G_L533P GAC_CTG > GGC_CCC 3 1 (33) 16 4 1 16 1
16 1 1
16 0.5 1
S531Q TCG > CAG 1 0 16 2 1
H526P CAC > CCC 1 0 16 4 1
H526R CAC > CGC 1 0 16 4 1
H526L CAC > CTC 1 1 4 0.12 1
Ins F at 514 Ins-3 bp TTC 1 1 8 0.5 1
WT∗ 9 5 (56) 16 4 1 16 0.5
16 1 3
16 0.5 1
16 0.25 2
4 0.25 1
4 0.12 1
Total 189
∗WT, wild type – no mutations in rpoB RRDR.
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FIGURE 1 | Comparison of RIF and RIFB MIC ranges and medians by rpoB mutations. A kruskal-Wallis test was used to show the association of MIC levels
of RIF and RIFB with the rpoB mutations. The eclplot was constructed with Stata 14.
selected RIF-resistant strains of M. tuberculosis, indicating
that the evolution of resistance is significantly constrained by
structural requirements of the RNA polymerase (Morlock et al.,
2000).
Current guidelines recommend RFB for treatment of TB
patients with HIV co-infection or poor tolerance to RIF, only
after safety and efficacy of the drug has been demonstrated
(Nettles et al., 2004; Li et al., 2005; Horne et al., 2011).
However, despite the known sterilizing properties of rifamycins,
no randomized controlled trials have investigated the use of
RFB in treatment of MDR-TB. The results of our study show
that a proportion of MDR-TB cases may potentially benefit
from the inclusion of RFB in chemotherapeutic regimens.
Relevant clinical studies are needed to establish appropriate
RFB-based regimens for achieving improved clinical outcome,
particularly in HIV endemic regions. Our findings additionally
support an association between specific rpoB mutations and
RFB susceptibility, which can have implications for expanding
therapeutic options in MDR-TB. For example, while rpoB
mutations would not provide definitive classification of RFB
susceptibility, molecular assays could be used as a basis for
targeted susceptibility testing in MDR-TB patients.
The limitations of our study include the use of CLSI
recommended clinical breakpoints for susceptibility testing of
RFB (CLSI, 2011). However, a recent review and a study from
a low HIV-TB prevalence setting have both suggested that the
current breakpoint of 0.5 mg/L may be in need of revision
(Schon et al., 2013; Crabol et al., 2016). In addition, as our
study was focused on MDR-TB, our population of clinical isolates
did not include any RIF-susceptible strains. Finally, as clinical
data and patient demographics were not available for this study,
we were not able to determine the HIV status of individual
cases.
The study identified three novel mutations outside of the
RRDR (V276L, V252E, and V276F) in RIF-resistant isolates,
supporting inclusion of the 5′-end of rpoB in molecular
testing for RIF/RFB resistance, as previously suggested (Tan
et al., 2012). Moreover, the wide range of MICs seen in
isolates with the same rpoB mutations suggests that other, as
yet unidentified, genes may be contributing to the observed
resistance levels. The presence of other genes that can confer
resistance to rifamycins is also supported by our finding that
5% of clinical MDR isolates in the collection contained a wild
type rpoB gene, two of which showed low level resistance
to RBT. This observation is consistent with other studies,
showing up to 5% of RIF-resistance in clinical isolates is not
explained by mutations in rpoB (Ramaswamy and Musser, 1998;
Sandgren et al., 2009) and by a recent report identifying a
phosphotransferase in M. tuberculosis capable of inactivating
RIF (Qi et al., 2016). The use of whole genome sequencing of
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clinical isolates of M. tuberculosis would be helpful in expanding
our understanding molecular mechanisms of drug resistance.
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